StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Vir Biotechnology cash

Cash and short-term investments held at the end of each period.

Vir Biotechnology's cash was $528.59M at Jun 30, 2026. For fiscal 2025 it was $460.94M, down 53.8% from the year before. The highest annual figure on record is $2.40B in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$460.94M-53.8%
FY2024Dec 31, 2024$996.75M-38.8%
FY2023Dec 31, 2023$1.63B-32.1%
FY2022Dec 31, 2022$2.40B+163.9%
FY2021Dec 31, 2021$909.50M+23.4%
FY2020Dec 31, 2020$736.90M+85.7%
FY2019Dec 31, 2019$396.92M+260.2%
FY2018Dec 31, 2018$110.21M-41.7%
FY2017Dec 31, 2017$188.92M+1238.5%
FY2016Dec 31, 2016$14.11M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$528.59M-11.7%
Q1 FY2026Mar 31, 2026$470.44M-40.5%
Q4 FY2025Dec 31, 2025$460.94M-53.8%
Q3 FY2025Sep 30, 2025$497.83M-58.2%
Q2 FY2025Jun 30, 2025$598.75M-58.1%
Q1 FY2025Mar 31, 2025$790.94M-47.6%
Q4 FY2024Dec 31, 2024$996.75M-38.8%
Q3 FY2024Sep 30, 2024$1.19B-30.0%
Q2 FY2024Jun 30, 2024$1.43B-24.7%
Q1 FY2024Mar 31, 2024$1.51B-34.3%
Q4 FY2023Dec 31, 2023$1.63B-32.1%
Q3 FY2023Sep 30, 2023$1.70B-29.2%
Q2 FY2023Jun 30, 2023$1.90B-17.4%
Q1 FY2023Mar 31, 2023$2.30B+64.3%
Q4 FY2022Dec 31, 2022$2.40B+163.9%
Q3 FY2022Sep 30, 2022$2.40B+155.5%
Q2 FY2022Jun 30, 2022$2.30B+162.3%
Q1 FY2022Mar 31, 2022$1.40B+91.0%
Q4 FY2021Dec 31, 2021$909.50M+23.4%
Q3 FY2021Sep 30, 2021$939.50M+13.7%
Q2 FY2021Jun 30, 2021$876.70M+58.7%
Q1 FY2021Mar 31, 2021$733.00M+106.1%
Q4 FY2020Dec 31, 2020$736.90M+85.7%
Q3 FY2020Sep 30, 2020$826.60M+158.2%
Q2 FY2020Jun 30, 2020$552.40M+584.7%
Q1 FY2020Mar 31, 2020$355.61M+449.4%
Q4 FY2019Dec 31, 2019$396.92M+260.2%
Q3 FY2019Sep 30, 2019$320.20M+571.7%
Q2 FY2019Jun 30, 2019$80.68M-57.3%
Q1 FY2019Mar 31, 2019$64.72M+358.6%
Q4 FY2018Dec 31, 2018$110.21M–
Q3 FY2018Sep 30, 2018$47.67M–
Q4 FY2017Dec 31, 2017$188.92M–
Q4 FY2016Dec 31, 2016$14.11M–

More Vir Biotechnology figures

See a number that looks wrong?